Watching
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very glad to see some strength at close. $MEDIF
Real nice action today
Nice! Tick tock.
Keep em coming MediPharm!
3rd quarter fins in about a month. Can't wait. $VFF
Nice close!
Bring us a strong close MediPharm...we've been patient.
Ready to see increased value given to those companies who are performing. "Promising" results while handing out shares like candy isn't going to cut it in Canada anymore. $LABS/MEDIF
Agreed. While I'm bullish on LABS/MEDIF, the sector needs to confirm a reverse and uptrend before I get too excited. Because I have some MEDIF shares under $1.50 I've held a core position throughout this mayhem. The market needs to start differentiating between the golden winners and pyrite.
Get. It. Done. :)
Nice close
Got my popcorn. $MEDIF/LABS
Nice to see the LABS/MEDIF footprint getting larger. Everything else is just noise. Bring the Revs MediPharm.
From what I heard it’s a question of when inspectors have a chance to inspect. Not sure if they’re waiting for Australia to open or not. I would think there would also have to be a record over time of GMP compliant production results to show consistency in processing. I’m trying to be patient. Lol
Quote: Patrick McCutcheon, Chief Executive Officer, MediPharm Labs. “In addition to our expertise in producing high-quality distillate and ability to provide stable supply, we are excited to explore the potential of global and US growth opportunities with TerrAscend as we work towards our final EuGMP certification.”
Give us GMP cert and we win.
Agreed, just waiting for the market to show some appreciation for one of its leaders. Once that switch is flipped we should have a very nice ride ahead of us. Trying to contain my enthusiasm until then. $MEDIF/LABS long. GLTA
MediPharm Labs Enters European Medical Cannabis Market with German Pharmaceutical and Medical Cannabis Distributor ADREXpharma®
First extraction-only company with supply agreement for export to Germany
Second international distribution milestone further expands the Company’s global supply chain
Demonstrates increasing international export potential in 2020
TORONTO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has signed its first private label sales agreement for export to Europe, with ADREXpharma® GmbH (“ADREXpharma”), a leading licensed wholesale distributor of controlled drugs and medical cannabis which can serve all of the approximate 20,000 pharmacies across Germany. Through its private label solutions platform, MediPharm Labs will supply ADREXpharma with high quality, purity assured, cannabis concentrate derivative products, including THC and CBD oil, for sale and distribution under the ADREXpharma brand in Germany upon receipt of applicable regulatory approvals.
“Germany is one of the largest and fastest growing medical cannabis markets in the world and represents MediPharm Labs’ second major international milestone as we prepare to export our private label cannabis concentrates into Germany,” said Pat McCutcheon, CEO of MediPharm Labs. “We are excited to be partnering with ADREXpharma, leveraging their deep expertise and local distribution to bring high quality, purity assured cannabis derivative products into the German market and expand our international exports.”
“MediPharm Labs shares our patient-centric focus and is an ideal partner for us to serve German patients in need,” said Mario Eimuth, Chief Executive Officer, ADREXpharma. “We are thrilled to partner with MediPharm Labs to extend our product range within the medicinal cannabis market with the highest pharmaceutical quality and to bring MediPharm Labs’ expertise in the cannabis extraction business to Germany.”
About the German Medical Cannabis Market
The German medical cannabis market has become one of the largest growing medical cannabis markets outside of North America. According to a Bank of Montreal report dated August 25, 2019, since legalization in 2017, German medical cannabis patient numbers have increased from 1,000 to an estimated 30,000 – 50,000 patients with patients paying higher average prices than in Canada. Further, another report published by the Bank of Montreal in November 2018 estimated the European Union medical cannabis market size could reach $30 billion by 2026.
About ADREXpharma
ADREXpharma® GmbH is an independent German pharmaceutical company which is specialized in the development and distribution of medicinal cannabis in the European market. ADREXpharma developed several dosages (extracts, powder, resin, flowers) for the growing pharma market in Germany. Due to its unique supply network, ADREXpharma can serve all of the approximate 20,000 pharmacies in Germany. ADREXpharma is committed to quality, authenticity and innovation, as well as to contributing to the growing body of evidence-based research regarding the benefits and efficacy of cannabis to validate new therapy options for patients. ADREXpharma’s aim is to provide the best possible treatment for medical cannabis patients - today and always.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.
For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the export of cannabis products to Germany and receipt and timing of applicable regulatory approvals therefor, the ultimate distribution of product to German pharmacies, the completion of MediPharm Labs’ Australian facility and timing thereof, and expected processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
https://web.tmxmoney.com/article.php?newsid=7547876814659254&qm_symbol=LABS
Nice news. Keep em coming
Karma. It's coming. $GRUSF
Other companies can hype and promise all they want. MediPharm is bringing the revenue. When it happens GMP cert. and Nasdaq will leave 95% of the Canadian sector in the dirt. Have a nice day! :)
$LABS/MEDIF giddyup
Let's get outta the gutter. Bring some news and move.
Good to see some deals announced. GLTA
Need some fresh news. Bring that revenue MediPharm. $MEDIF/LABS
Can't wait to see what the next few months brings. $VFF
Nextleaf Solutions Granted U.S. Patent for THC and CBD Oil Processing
Canada NewsWire
VANCOUVER, Sept. 10, 2019
Patented technology allows for dried cannabis and hemp biomass to be efficiently processed into a high-purity distilled oil, simplifying the manufacturing of differentiated THC and CBD formulations and delivery methods
VANCOUVER, Sept. 10, 2019 /CNW/ - Nextleaf Solutions Ltd. ("Nextleaf", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) announced today it has been granted a fifth patent, its fourth in the United States, pertaining to the Company's proprietary technology for extraction and post-extraction processing of cannabinoids.
Nextleaf Solutions Ltd. (CNW Group/Nextleaf Solutions Ltd.)
This most recently issued patent integrates a process by which brine is introduced to the crude oil to efficiently remove water-soluble compounds, impurities, and any other trace elements of treatment media. The result is a highly pure input, leading to faster processing times for further patented post-extraction processing, resulting in a lower cost per milligram for the highly refined THC or CBD concentrate.
"It has been our vision since inception that intellectual property would become a key differentiator and value creator in the cannabis industry," stated Paul Pedersen, Chief Executive Officer of Nextleaf. "With five issued and 25 pending patents covering what we believe to be the most efficient method of extraction and purification of cannabinoids, Nextleaf is well positioned to monetize our intellectual property as we move into Cannabis 2.0 in Canada and beyond," added Pedersen.
OILS remains focused on acquiring, developing, and patenting the industry's most advanced market-proven technology, equipment, and processes around the extraction and purification of cannabinoids. The Company's patented process yields a tasteless, odorless THC or CBD distillate, manufactured at scale, standardized for potency, and ready for infusion in value-add products, such as vape technology, edible oils, and beverages.
On Behalf of the Board of Directors of the Company,
Paul Pedersen, Co-Founder & CEO
About Nextleaf Solutions
Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial-scale extraction and purification of cannabinoids. Nextleaf owns a portfolio of five (5) issued and 25 pending patents pertaining to the production of high-purity, cannabinoid rich distillate, a key ingredient used in the manufacturing of standardized THC and CBD infused products. Once cannabis concentrates become legal across Canada on October 17, 2019, the Company plans to commercialize its intellectual property portfolio through IP licensing and B2B processing services.
Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB Market in the United States (OTCQB: OILFF) and L0MA on the Frankfurt Stock Exchange (FSE: L0MA)
Contact:
Adel Fares, Investor Relations
604-283-2301 (ext. 201)
investors@nextleafsolutions.com
For more information visit www.nextleafsolutions.com or follow OILS across social media platforms: Twitter, LinkedIn, Facebook, Instagram and YouTube.
CAUTIONARY STATEMENT:
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio, expectations regarding lower concentrate costs resulting from utilization of the Company's technology, levels of purity resulting from the Company's patented technology, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed, approved or disapproved the contents of this press release.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nextleaf-solutions-granted-us-patent-for-thc-and-cbd-oil-processing-300915330.html
SOURCE Nextleaf Solutions Ltd.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/10/c5379.html
Copyright CNW Group 2019
https://web.tmxmoney.com/article.php?newsid=8172101626402644&qm_symbol=OILS:CNX
Nextleaf Solutions Announces Health Canada Standard Processing Licence Issued to Nextleaf Labs
VANCOUVER, Sept. 9, 2019 /PRNewswire/ - Nextleaf Solutions Ltd. ("Nextleaf Solutions", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) announced today that Nextleaf Labs Ltd. ("Nextleaf Labs" or "Labs"), has received its Standard Processing Licence from Health Canada. This represents an important milestone for Nextleaf Solutions, allowing OILS to commercialize its intellectual property ("IP") portfolio through the production of cannabis oils and concentrates.
Nextleaf Solutions owns a portfolio of four (4) issued and 25 pending patents pertaining to the industrial-scale extraction and purification of cannabinoids, such as THC and CBD. The Company's patented cryo-ethanol extraction, filtration, refinement and molecular distillation process and hardware will support the manufacturing of standardized THC and CBD based products. Since 2017, Nextleaf Solutions has been focused on acquiring, developing, and protecting IP that enhances cannabis oil economics. OILS aims to capitalize on its first mover technical advantage, with Canada set to become the first G20 country to legalize the production and sale of cannabis oils, concentrates, and edibles later this year.
Currently, Nextleaf Labs licenses the Company's IP and infrastructure in British Columbia pursuant to a licensing agreement. As a result of the receipt of the Health Canada Standard Processing Licence by Nextleaf Labs on September 6, 2019, Labs will begin utilizing the Company's IP portfolio to commence B2B toll processing and white label production of cannabis oils and concentrates for qualified Canadian and international partners under their own brand.
"Our vision is to develop technology to revolutionize extraction throughput, yield, and purity to enhance cannabis oil economics across the globe" said Paul Pedersen, CEO of Nextleaf Solutions. "We are beyond excited to begin commercializing OILS' intellectual property portfolio for industrial-scale extraction and purification of CBD and THC", continued Mr. Pedersen.
About Nextleaf Solutions
Nextleaf Solutions Ltd. ("OILS") is the first publicly traded company to be issued a patent for the industrial-scale extraction and purification of cannabinoids. OILS owns a portfolio of four (4) issued and 25 pending patents pertaining to the production of high-purity cannabinoid distillate, the precursor used in the manufacturing of standardized THC and CBD based products. Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB in the United States (OTCQB: OILFF) and L0MA on the Frankfurt Stock Exchange (FSE: L0MA).
On Behalf of the Board of Directors of the Company,
Paul Pedersen, Co-Founder & CEO
Contact:
Adel Fares, Investor Relations
604-283-2301 (ext. 201)
investors@nextleafsolutions.com
For more information visit www.nextleafsolutions.com or follow OILS across social media platforms: Twitter, LinkedIn, Facebook, Instagram and YouTube.
CAUTIONARY STATEMENT:
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio and enter into agreements with third parties, expected market growth, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed, approved or disapproved the contents of this press release.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nextleaf-solutions-announces-health-canada-standard-processing-licence-issued-to-nextleaf-labs-300913848.html
SOURCE Nextleaf Solutions Ltd.
https://web.tmxmoney.com/article.php?newsid=7646688930353825&qm_symbol=OILFF:US
First good night of sleep in a week. Ready to turn up the volume. GLTA
Abracadabra
Summer over yet? Bring the heat Village.
Let's gooo. Ready for the season to begin.
Been having tech issues in the office last couple days..I couldn't verify if that was a glitch or not. :)
Either way....ready for these markets to settle.
Come on, let's close green. $MEDIF/LABS
Exactly. :)
Yes sir..might as well stay current while we wait for the market to realize how undervalued we are. lol
July 2019 Investor Presentation
http://villagefarms.com/wp-content/uploads/2014/08/VFF-Investor-Presentation-July-for-Web-Site-Jul-17.pdf
Management Investor Presentation August 2019
https://d1io3yog0oux5.cloudfront.net/_f077e2b428435892ae6390797acaf37a/medipharmlabs/db/357/2889/pdf/MediPharm+Labs+-+August+12+2019+-+Final.pdf